NPM1 and acute myeloid leukemia: In their retrospective analysis of MRD results of the AMLSG 09-09 trial including NPM1 mutated AML patients who received chemotherapy (standard arm) or chemotherapy + gemtuzumab ozogamycin (GO), Schwoerer et al. were able to show a significant increase in MRD-negative patients in the intervention arm receiving GO, which resulted in a statistically significant reduction of the cumulative incidence of relapse [96].